The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1636
November 1, 2021
View Complete Issue         Table of Contents 2019 
Trilaciclib (Cosela) for Prevention of Chemotherapy-Related Myelosuppression
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Trilaciclib (Cosela) for Prevention of Chemotherapy-Related Myelosuppression
November 1, 2021 (Issue: 1636)
The FDA has approved trilaciclib (Cosela – G1 Therapeutics), a cyclin-dependent kinase (CDK) 4/6 inhibitor, to decrease the incidence of chemotherapy-induced myelosuppression in adults receiving a platinum/etoposide- or topotecan-containing...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Trilaciclib (Cosela) for Prevention of Chemotherapy-Related Myelosuppression
Article code: 1636d
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.